1643 (1643) Fair Value & Analysis

Healthcare · Market cap HK$864M

1 1643 1643 · HK

PriceHK$1.20

Fair ValueHK$0.3900

Upside-67.5%

Quality44/100

Watch 1643 for free — get notified when fair value or trend changes. Watch for free

Evidence: Low Range HK$0.2600 – HK$0.4800

Fair value as of: Jul 2, 2026

From 1 valuation models · updated today

Share price −46.4% over the past month.

Price vs Fair Value (12 months)

12‑month range HK$0.3381 – HK$3.05 · fair‑value band HK$0.2600 – HK$0.4800 · the HK$1.20 price screens above the HK$0.3900 fair value. As of Jul 2, 2026.

✦ Which stocks are undervalued right now? Check free Discover now →

Analysis

1643 (1643) currently trades at HK$1.20, while our model-based Fair Value estimate is HK$0.3900 — implying the stock looks roughly 67.5% overvalued today. We read business quality at 44/100 (below-average quality), in the Healthcare sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium — the entry price still matters most (evidence: low).

Over the trailing twelve months, 1643 generated revenue of HK$145M at a net margin of -9.3%. Revenue declined 41.5% year over year. It earns a return on equity of -2.8%. The balance sheet holds a net cash position of HK$230M. Fundamentals as of Jul 2, 2026

Key figures & financial health

Revenue (TTM) HK$145M

Revenue growth (YoY) -41.5%

Net margin -9.3%

Return on equity -2.8%

Free cash flow −HK$16.6M FY2025

Operating margin -23.1%

More key figures

EPS growth (YoY) -22.1%

Net cash HK$230M FY2025

Figures from reported company fundamentals (EODHD) · as of Jul 2, 2026. TTM = trailing twelve months.

Revenue & earnings trend

FY2021 – FY2025 · reported fiscal years

1643 reported revenue of HK$141M in FY2025 versus HK$361M in FY2021, a compound −20.9%/yr. Reported net income was −HK$13.2M in FY2025.

Revenue −20.9%/yr

FY21 HK$361M

FY22 HK$400M

FY23 HK$344M

FY24 HK$214M

FY25 HK$141M

Net income

FY21 HK$81.8M

FY22 HK$87.8M

FY23 HK$48.8M

FY24 HK$9.7M

FY25 −HK$13.2M

Is 1643 fairly valued? → Check now

Similar stocks

6 more Drug Manufacturers - General stocks, each showing price versus our Fair Value estimate (as of Jul 2, 2026).

Stock	Price	Fair Value	vs Fair Value
Eli Lilly and Company LLY	$1,107	$395.92	-64%
JNJ JNJ	4,128 MXN	159.68 MXN	-96%
Johnson & Johnson, JNJB34	R$78.54	R$47.48	-40%
AbbVie Inc ABBV	$224.95	$129.90	-42%
Roche Holding ROGN	7,050 MXN	316.37 MXN	-96%
Merck & Co MRK	$115.48	$127.57	+10%

Explore undervalued stocks

More undervalued Healthcare stocks →

All undervalued stocks Technology Financial Services Healthcare Consumer Cyclical Consumer Defensive Communication Services Industrials Energy Basic Materials Real Estate Utilities Deeply Undervalued Stocks Undervalued Blue-Chip Stocks Undervalued Small-Cap Stocks

Frequently asked questions

Is 1643 (1643) undervalued?

As of Jul 2, 2026, our model estimates a fair value of HK$0.3900 versus a price of HK$1.20 — about −68% (overvalued). Model-based estimate, not financial advice.

What is the fair value of 1643?

Our model-based fair value for 1643 is HK$0.3900 (as of Jul 2, 2026), built from audited fundamentals. The current price is HK$1.20.

What is the quality score of 1643?

1643 has a Quality Score of 44/100, measuring profitability, growth and balance-sheet strength from non-valuation factors.

What is the revenue of 1643 (1643)?

1643 reported trailing-twelve-month revenue of about HK$145M (latest available figure, as of Jul 2, 2026).

What is the net profit margin of 1643?

The net profit margin of 1643 is about -9.3%, meaning it is currently running at a net loss. Based on the latest reported figures.

How we calculate Fair Value

Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.

Educational research only · not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.